<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2025//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_250101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="Publisher" Owner="NLM"><PMID Version="1">40782958</PMID><DateRevised><Year>2025</Year><Month>08</Month><Day>24</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Print">0210-5705</ISSN><JournalIssue CitedMedium="Internet"><PubDate><Year>2025</Year><Month>Aug</Month><Day>07</Day></PubDate></JournalIssue><Title>Gastroenterologia y hepatologia</Title><ISOAbbreviation>Gastroenterol Hepatol</ISOAbbreviation></Journal><ArticleTitle>Duodenal cystic dystrophy with a final diagnosis of pancreatic adenocarcinoma: Direct relationship or incidental finding?</ArticleTitle><Pagination><StartPage>502534</StartPage><MedlinePgn>502534</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.gastrohep.2025.502534</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S0210-5705(25)00404-2</ELocationID><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Fern&#xe1;ndez Rodriguez</LastName><ForeName>Pablo</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Servicio de Aparato Digestivo, Hospital Universitario de la Princesa, Instituto de Investigaci&#xf3;n Sanitaria Princesa (IIS-IP), Universidad Aut&#xf3;noma de Madrid; Centro de Investigaci&#xf3;n Biom&#xe9;dica en Red de Enfermedades Hep&#xe1;ticas y Digestivas (CIBERHD), Madrid, Espa&#xf1;a. Electronic address: pabferrod5@gmail.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Castillo G&#xe1;zquez</LastName><ForeName>Lidia</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Servicio de Anatom&#xed;a Patol&#xf3;gica, Hospital Universitario de la Princesa, Madrid, Espa&#xf1;a.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>&#xc1;lvarez Mal&#xe9;</LastName><ForeName>Tom&#xe1;s</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Servicio de Aparato Digestivo, Hospital Universitario de la Princesa, Instituto de Investigaci&#xf3;n Sanitaria Princesa (IIS-IP), Universidad Aut&#xf3;noma de Madrid; Centro de Investigaci&#xf3;n Biom&#xe9;dica en Red de Enfermedades Hep&#xe1;ticas y Digestivas (CIBERHD), Madrid, Espa&#xf1;a.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jim&#xe9;nez G&#xf3;mez</LastName><ForeName>Mirella</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Servicio de Aparato Digestivo, Hospital Universitario de la Princesa, Instituto de Investigaci&#xf3;n Sanitaria Princesa (IIS-IP), Universidad Aut&#xf3;noma de Madrid; Centro de Investigaci&#xf3;n Biom&#xe9;dica en Red de Enfermedades Hep&#xe1;ticas y Digestivas (CIBERHD), Madrid, Espa&#xf1;a.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><Language>spa</Language><PublicationTypeList><PublicationType UI="D016422">Letter</PublicationType></PublicationTypeList><VernacularTitle>Distrofia qu&#xed;stica duodenal con diagn&#xf3;stico final de adenocarcinoma de p&#xe1;ncreas: &#xbf;relaci&#xf3;n directa o hallazgo casual?</VernacularTitle><ArticleDate DateType="Electronic"><Year>2025</Year><Month>08</Month><Day>07</Day></ArticleDate></Article><MedlineJournalInfo><Country>Spain</Country><MedlineTA>Gastroenterol Hepatol</MedlineTA><NlmUniqueID>8406671</NlmUniqueID><ISSNLinking>0210-5705</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2025</Year><Month>4</Month><Day>2</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2025</Year><Month>7</Month><Day>21</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2025</Year><Month>7</Month><Day>25</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>8</Month><Day>10</Day><Hour>6</Hour><Minute>16</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>8</Month><Day>10</Day><Hour>6</Hour><Minute>16</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>8</Month><Day>9</Day><Hour>19</Hour><Minute>36</Minute></PubMedPubDate></History><PublicationStatus>aheadofprint</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">40782958</ArticleId><ArticleId IdType="doi">10.1016/j.gastrohep.2025.502534</ArticleId><ArticleId IdType="pii">S0210-5705(25)00404-2</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">40721024</PMID><DateCompleted><Year>2025</Year><Month>09</Month><Day>04</Day></DateCompleted><DateRevised><Year>2025</Year><Month>09</Month><Day>05</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">2173-5794</ISSN><JournalIssue CitedMedium="Internet"><Volume>100</Volume><Issue>9</Issue><PubDate><Year>2025</Year><Month>Sep</Month></PubDate></JournalIssue><Title>Archivos de la Sociedad Espanola de Oftalmologia</Title><ISOAbbreviation>Arch Soc Esp Oftalmol (Engl Ed)</ISOAbbreviation></Journal><ArticleTitle>Ambispective study on the phenotypic progression of patients with Stargardt disease associated with ABCA4 gene mutations.</ArticleTitle><Pagination><StartPage>528</StartPage><EndPage>536</EndPage><MedlinePgn>528-536</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.oftale.2025.07.012</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S2173-5794(25)00128-8</ELocationID><Abstract><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">This study aims to describe the phenotypic progression of patients with Stargardt disease caused by mutations in the ABCA4 gene and reports on the mutated allelic variants.</AbstractText><AbstractText Label="METHOD" NlmCategory="METHODS">We conducted an observational, ambispective, and descriptive study. Patients who had Stargardt disease by the ABCA4 gene mutation were included. The study used the genetic report and the baseline examinations appearing on health records. To evaluate the phenotypic variation, a new ophthalmological evaluation was conducted using macular OCT, retinography, autofluorescence, and electroretinogram.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">The study identified a total of 32 cases with a mean follow-up of 6 years. The mean age of onset was 16 years. The mean initial and final VA were 0.79 and 0.95 logMAR, respectively. The mean initial and final CMT were 142.5 and 135 microns, respectively. The predominant degree of fundus involvement and autofluorescence pattern at the beginning and end was macular atrophy with flecks and the low signal of macular autofluorescence surrounded by a heterogeneous background, respectively. Initial electroretinography showed predominantly preserved function of rods and cones, while in the end most cases presented rod and cone system dysfunction. A total of 9 cases were homozygous, and 31 different mutant allelic variants were identified. The most common variant was p.Trp1618Cys, followed by p.Ala1773Val. Two new allelic variants, p.Leu634Pro, and p.Tyr665Serfs*5, were also discovered.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">The study found that patients experienced structural and functional deterioration at the follow-up. The study also identified 2 predominant variants and 2 new variants. Homozygotes had an earlier onset of the disease.</AbstractText><CopyrightInformation>Copyright &#xa9; 2025 Sociedad Espa&#xf1;ola de Oftalmolog&#xed;a. Published by Elsevier Espa&#xf1;a, S.L.U. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Martel Ramirez</LastName><ForeName>V A</ForeName><Initials>VA</Initials><AffiliationInfo><Affiliation>Departamento de Retina y V&#xed;treo, Fundaci&#xf3;n Hospital Nuestra Se&#xf1;ora de la Luz IAP, Mexico City, Mexico. Electronic address: martelramirezangel1@gmail.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>P&#xe9;rez Monta&#xf1;o</LastName><ForeName>C R</ForeName><Initials>CR</Initials><AffiliationInfo><Affiliation>Departamento de Retina y V&#xed;treo, Fundaci&#xf3;n Hospital Nuestra Se&#xf1;ora de la Luz IAP, Mexico City, Mexico.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hern&#xe1;ndez V&#xe1;zquez</LastName><ForeName>A Y</ForeName><Initials>AY</Initials><AffiliationInfo><Affiliation>Departamento de Retina y V&#xed;treo, Fundaci&#xf3;n Hospital Nuestra Se&#xf1;ora de la Luz IAP, Mexico City, Mexico.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rojas Ju&#xe1;rez</LastName><ForeName>S</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Departamento de Retina y V&#xed;treo, Fundaci&#xf3;n Hospital Nuestra Se&#xf1;ora de la Luz IAP, Mexico City, Mexico.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ram&#xed;rez Estudillo</LastName><ForeName>J A</ForeName><Initials>JA</Initials><AffiliationInfo><Affiliation>Departamento de Retina y V&#xed;treo, Fundaci&#xf3;n Hospital Nuestra Se&#xf1;ora de la Luz IAP, Mexico City, Mexico.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D064888">Observational Study</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2025</Year><Month>07</Month><Day>26</Day></ArticleDate></Article><MedlineJournalInfo><Country>Spain</Country><MedlineTA>Arch Soc Esp Oftalmol (Engl Ed)</MedlineTA><NlmUniqueID>101715860</NlmUniqueID><ISSNLinking>2173-5794</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C056475">ABCA4 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018528">ATP-Binding Cassette Transporters</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000080362" MajorTopicYN="Y">Stargardt Disease</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018528" MajorTopicYN="Y">ATP-Binding Cassette Transporters</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010641" MajorTopicYN="N">Phenotype</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009154" MajorTopicYN="Y">Mutation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018450" MajorTopicYN="N">Disease Progression</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D055815" MajorTopicYN="N">Young Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002648" MajorTopicYN="N">Child</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004596" MajorTopicYN="N">Electroretinography</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D041623" MajorTopicYN="N">Tomography, Optical Coherence</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008268" MajorTopicYN="Y">Macular Degeneration</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000151" MajorTopicYN="N">congenital</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005500" MajorTopicYN="N">Follow-Up Studies</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">ABCA4 gene</Keyword><Keyword MajorTopicYN="N">Distrofia de retina</Keyword><Keyword MajorTopicYN="N">Enfermedad de Stargardt</Keyword><Keyword MajorTopicYN="N">Gen ABCA4</Keyword><Keyword MajorTopicYN="N">Retinal dystrophy</Keyword><Keyword MajorTopicYN="N">Stargardt disease</Keyword></KeywordList><CoiStatement>Conflicts of interest The authors declare that there are no potential conflicts of interest of this article.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2023</Year><Month>11</Month><Day>20</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2025</Year><Month>6</Month><Day>6</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>9</Month><Day>5</Day><Hour>0</Hour><Minute>35</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>7</Month><Day>29</Day><Hour>0</Hour><Minute>57</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>7</Month><Day>28</Day><Hour>19</Hour><Minute>33</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">40721024</ArticleId><ArticleId IdType="doi">10.1016/j.oftale.2025.07.012</ArticleId><ArticleId IdType="pii">S2173-5794(25)00128-8</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">40489651</PMID><DateCompleted><Year>2025</Year><Month>06</Month><Day>09</Day></DateCompleted><DateRevised><Year>2025</Year><Month>06</Month><Day>14</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">2448-5667</ISSN><JournalIssue CitedMedium="Internet"><Volume>63</Volume><Issue>Suppl 1</Issue><PubDate><Year>2025</Year><Month>Jan</Month><Day>02</Day></PubDate></JournalIssue><Title>Revista medica del Instituto Mexicano del Seguro Social</Title><ISOAbbreviation>Rev Med Inst Mex Seguro Soc</ISOAbbreviation></Journal><ArticleTitle>[Benefits of &#x3c9;-3 fatty acids in Duchenne muscular dystrophy].</ArticleTitle><Pagination><StartPage>e6316</StartPage><MedlinePgn>e6316</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">e6316</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.5281/zenodo.14199927</ELocationID><Abstract><AbstractText>Duchenne Muscular Dystrophy (DMD), caused by mutations in the dystrophin gene, is the most common congenital muscular dystrophy and is characterized by a chronic inflammatory response mediated by immune cells and cytokines. Obesity, a common feature of DMD, exacerbates this inflammation. Although corticosteroids are the conventional treatment, their adverse effects are substantial. The use of omega-3 polyunsaturated fatty acids (PUFA&#x3c9;-3) as adjuvant therapy is under investigation. A comprehensive review of studies from 2011 to May 2024 reveals that supplementation with PUFA&#x3c9;-3 has beneficial effects in mdx mice, a model of DMD. These include reduction of the inflammatory process in both muscle and circulation, in addition to decreased myonecrosis, resulting in improved muscle strength and endurance. Supplementation also had a positive impact on cardiac tissue, reducing fibrosis and inflammation present in this tissue. These results were corroborated in patients with DMD. A significant decrease in inflammatory markers such as NF-kB, IL-1&#x3b2; and IL-6 was observed with PUFA&#x3c9;-3, and an increase in the anti-inflammatory cytokine IL-10, suggesting a potential anti-inflammatory effect. These findings support the use of PUFA&#x3c9;-3 as adjuvant therapy in DMD, although further research is needed to fully understand its mechanisms and clinical benefits.</AbstractText><CopyrightInformation>Licencia CC 4.0 (BY-NC-ND) &#xa9; 2025 Revista M&#xe9;dica del Instituto Mexicano del Seguro Social.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Galeazzi-Aguilar</LastName><ForeName>Jos&#xe9; Emilio</ForeName><Initials>JE</Initials><Identifier Source="ORCID">0009-0002-6664-4178</Identifier><AffiliationInfo><Affiliation>Universidad Nacional Aut&#xf3;noma de M&#xe9;xico, Facultad de Medicina, Posgrado en Ciencias Biom&#xe9;dicas. Ciudad de M&#xe9;xico, M&#xe9;xico.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rodr&#xed;guez-Cruz</LastName><ForeName>Maricela</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0001-8496-4023</Identifier><AffiliationInfo><Affiliation>Instituto Mexicano del Seguro Social, Centro M&#xe9;dico Nacional Siglo XXI, Hospital de Pediatr&#xed;a "Dr. Silvester Frenk Freund", Unidad de Investigaci&#xf3;n M&#xe9;dica en Nutrici&#xf3;n. Ciudad de M&#xe9;xico, M&#xe9;xico.</Affiliation></AffiliationInfo></Author></AuthorList><Language>spa</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType><PublicationType UI="D004740">English Abstract</PublicationType></PublicationTypeList><VernacularTitle>Beneficios de los &#xe1;cidos grasos &#x3c9;-3 en la distrofia muscular de Duchenne.</VernacularTitle><ArticleDate DateType="Electronic"><Year>2025</Year><Month>01</Month><Day>02</Day></ArticleDate></Article><MedlineJournalInfo><Country>Mexico</Country><MedlineTA>Rev Med Inst Mex Seguro Soc</MedlineTA><NlmUniqueID>101243727</NlmUniqueID><ISSNLinking>0443-5117</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015525">Fatty Acids, Omega-3</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D020388" MajorTopicYN="Y">Muscular Dystrophy, Duchenne</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000178" MajorTopicYN="N">diet therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015525" MajorTopicYN="Y">Fatty Acids, Omega-3</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019587" MajorTopicYN="Y">Dietary Supplements</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018101" MajorTopicYN="N">Mice, Inbred mdx</DescriptorName></MeshHeading></MeshHeadingList><OtherAbstract Type="Publisher" Language="spa"><AbstractText>La distrofia muscular de Duchenne (DMD), causada por mutaciones en el gen de la distrofina, es la distrofia muscular cong&#xe9;nita m&#xe1;s frecuente y se caracteriza por una respuesta inflamatoria cr&#xf3;nica mediada por c&#xe9;lulas inmunitarias y citoquinas. La obesidad, caracter&#xed;stica com&#xfa;n en la DMD, exacerba esta inflamaci&#xf3;n. Aunque los corticosteroides son el tratamiento convencional, sus efectos adversos son sustanciales. El consumo de &#xe1;cidos grasos poliinsaturados omega-3 (AGPI &#x3c9;-3), como terapia adyuvante, podr&#xed;a ser de utilidad para disminuir la inflamaci&#xf3;n en la DMD. La revisi&#xf3;n exhaustiva de estudios desde 2011 y hasta mayo de 2024 revela que los AGPI &#x3c9;-3 tienen efectos beneficiosos en los ratones mdx, un modelo de la DMD. Estos incluyen la reducci&#xf3;n del proceso inflamatorio tanto en el m&#xfa;sculo como en la circulaci&#xf3;n, adem&#xe1;s de la disminuci&#xf3;n de mio-necrosis, resultando en mayor fuerza y resistencia muscular. La suplementaci&#xf3;n con AGPI &#x3c9;-3 tambi&#xe9;n tuvo un impacto positivo en el tejido card&#xed;aco, reduciendo la fibrosis y la inflamaci&#xf3;n. Estos hallazgos fueron consistentes con los observados en pacientes con DMD, se observ&#xf3; una disminuci&#xf3;n de marcadores inflamatorios como NF-kB, IL-1&#x3b2; e IL-6, y un aumento de la citoquina antiinflamatoria IL-10, lo que sugiere un potencial efecto antiinflamatorio. Estos hallazgos apoyan el uso de AGPI &#x3c9;-3 como terapia adyuvante en DMD, aunque se necesita investigaci&#xf3;n adicional para entender completamente sus mecanismos y beneficios cl&#xed;nicos.</AbstractText><CopyrightInformation>Licencia CC 4.0 (BY-NC-ND) &#xa9; 2025 Revista M&#xe9;dica del Instituto Mexicano del Seguro Social.</CopyrightInformation></OtherAbstract><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Body Composition</Keyword><Keyword MajorTopicYN="N">Fatty Acids, Omega-3</Keyword><Keyword MajorTopicYN="N">Inflammation</Keyword><Keyword MajorTopicYN="N">Insulin Resistance</Keyword><Keyword MajorTopicYN="N">Muscular Dystrophy, Duchenne</Keyword></KeywordList><CoiStatement>los autores han completado y enviado la forma traducida al espa&#xf1;ol de la declaraci&#xf3;n de conflictos potenciales de inter&#xe9;s del Comit&#xe9; Internacional de Editores de Revistas M&#xe9;dicas, y no fue reportado alguno relacionado con este art&#xed;culo.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>7</Month><Day>4</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>8</Month><Day>26</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>6</Month><Day>9</Day><Hour>18</Hour><Minute>29</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>6</Month><Day>9</Day><Hour>18</Hour><Minute>28</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>6</Month><Day>9</Day><Hour>15</Hour><Minute>20</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2025</Year><Month>1</Month><Day>1</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">40489651</ArticleId><ArticleId IdType="pmc">PMC12162134</ArticleId><ArticleId IdType="doi">10.5281/zenodo.14199927</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Salari N, Fatahi B, Valipour E, et al. Global prevalence of Duchenne and Becker muscular dystrophy: a systematic review and meta-analysis. J Orthop Surg Res. 2022;17(1):96. doi: 10.1186/s13018-022-02996-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13018-022-02996-8</ArticleId><ArticleId IdType="pmc">PMC8848641</ArticleId><ArticleId IdType="pubmed">35168641</ArticleId></ArticleIdList></Reference><Reference><Citation>Duan D, Goemans N, Takeda S, et al. Duchenne muscular dystrophy. Nat Rev Dis Primers. 2021;7(1):13. doi: 10.1038/s41572-021-00248-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41572-021-00248-3</ArticleId><ArticleId IdType="pmc">PMC10557455</ArticleId><ArticleId IdType="pubmed">33602943</ArticleId></ArticleIdList></Reference><Reference><Citation>Chang M, Cai Y, Gao Z, et al. Duchenne muscular dystrophy: pathogenesis and promising therapies. J Neurol. 2023;270(8):3733&#x2013;3749. doi: 10.1007/s00415-023-11796-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00415-023-11796-x</ArticleId><ArticleId IdType="pubmed">37258941</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu X, Dong N, Yu L, et al. Identification of immune-related features involved in Duchenne muscular dystrophy: A bidirectional transcriptome and proteome-driven analysis. Front Immunol. 2022;13:1017423. doi: 10.3389/fimmu.2022.1017423.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2022.1017423</ArticleId><ArticleId IdType="pmc">PMC9724784</ArticleId><ArticleId IdType="pubmed">36483550</ArticleId></ArticleIdList></Reference><Reference><Citation>Rosenberg AS, Puig M, Nagaraju K, et al. Immune-mediated pathology in Duchenne muscular dystrophy. Sci Transl Med. 2015;7(299) doi: 10.1126/scitranslmed.aaa7322.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/scitranslmed.aaa7322</ArticleId><ArticleId IdType="pmc">PMC5951380</ArticleId><ArticleId IdType="pubmed">26246170</ArticleId></ArticleIdList></Reference><Reference><Citation>Collins RA, Grounds MD. The role of Tumor Necrosis Factor-alpha (TNF-&#x3b1;) in skeletal muscle regeneration: studies in TNF-&#x3b1;(-/-) and TNF-&#x3b1;(-/-)/LT-&#x3b1;(-/-) Mice. J Histochem Cytochem. 2001;49(8):989&#x2013;1001. doi: 10.1177/002215540104900807.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/002215540104900807</ArticleId><ArticleId IdType="pubmed">11457927</ArticleId></ArticleIdList></Reference><Reference><Citation>Rodr&#xed;guez-Cruz M, Sanchez R, Escobar RE, et al. Evidence of insulin resistance and other metabolic alterations in boys with Duchenne or Becker muscular dystrophy. Int J Endocrinol. 2015;2015:1&#x2013;8. doi: 10.1155/2015/867273.</Citation><ArticleIdList><ArticleId IdType="doi">10.1155/2015/867273</ArticleId><ArticleId IdType="pmc">PMC4452344</ArticleId><ArticleId IdType="pubmed">26089900</ArticleId></ArticleIdList></Reference><Reference><Citation>Al-Roub A, Madhoun AA, Akhter N, et al. IL-1&#x3b2; and TNF&#x3b1; cooperativity in regulating IL-6 expression in adipocytes depends on CREB binding and H3K14 acetylation. Cells. 2021;10(11):3228. doi: 10.3390/cells10113228.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/cells10113228</ArticleId><ArticleId IdType="pmc">PMC8619559</ArticleId><ArticleId IdType="pubmed">34831450</ArticleId></ArticleIdList></Reference><Reference><Citation>Crupi R, Cuzzocrea S. Role of EPA in inflammation: mechanisms, effects, and clinical relevance. Biomolecules. 2022;12(2):242. doi: 10.3390/biom12020242.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/biom12020242</ArticleId><ArticleId IdType="pmc">PMC8961629</ArticleId><ArticleId IdType="pubmed">35204743</ArticleId></ArticleIdList></Reference><Reference><Citation>Machado RV, Mauricio AF, Taniguti APT, et al. Eicosapentaenoic acid decreases TNF-&#x3b1; and protects dystrophic muscles of mdx mice from degeneration. J Neuroimmunol. 2011;232(1-2):145&#x2013;150. doi: 10.1016/j.jneuroim.2010.10.032.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jneuroim.2010.10.032</ArticleId><ArticleId IdType="pubmed">21131061</ArticleId></ArticleIdList></Reference><Reference><Citation>De Carvalho SC, Matsumura CY, Santo-Neto H, et al. Identification of plasma interleukins as biomarkers for deflazacort and omega-3 based Duchenne muscular dystrophy therapy. Cytokine. 2018;102:55&#x2013;61. doi: 10.1016/j.cyto.2017.12.006.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cyto.2017.12.006</ArticleId><ArticleId IdType="pubmed">29276972</ArticleId></ArticleIdList></Reference><Reference><Citation>De Carvalho SC, Hindi SM, Kumar A, et al. Effects of omega-3 on matrix metalloproteinase-9, myoblast transplantation and satellite cell activation in dystrophin-deficient muscle fibers. Cell Tissue Res. 2017;369(3):591&#x2013;602. doi: 10.1007/s00441-017-2640-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00441-017-2640-x</ArticleId><ArticleId IdType="pubmed">28623422</ArticleId></ArticleIdList></Reference><Reference><Citation>Fogagnolo-Mauricio A, Pereira JA, Santo-Neto H, et al. Effects of fish oil containing eicosapentaenoic acid and docosahexaenoic acid on dystrophic mdx mice hearts at later stages of dystrophy. Nutrition. 2016;32(7-8):855&#x2013;862. doi: 10.1016/j.nut.2016.01.015.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.nut.2016.01.015</ArticleId><ArticleId IdType="pubmed">27134205</ArticleId></ArticleIdList></Reference><Reference><Citation>Fogagnolo-Mauricio A, De Carvalho SC, Santo-Neto H, et al. Effects of dietary omega-3 on dystrophic cardiac and diaphragm muscles as evaluated by 1H magnetic resonance spectroscopy: Metabolic profile and calcium-related proteins. Clin Nutr ESPEN. 2017;20:60&#x2013;67. doi: 10.1016/j.clnesp.2017.03.005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.clnesp.2017.03.005</ArticleId><ArticleId IdType="pubmed">29072171</ArticleId></ArticleIdList></Reference><Reference><Citation>Tripodi L, Molinaro D, Farini A, et al. Flavonoids and Omega3 prevent muscle and cardiac damage in Duchenne muscular dystrophy animal model. Cells. 2021;10(11):2917. doi: 10.3390/cells10112917.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/cells10112917</ArticleId><ArticleId IdType="pmc">PMC8616158</ArticleId><ArticleId IdType="pubmed">34831140</ArticleId></ArticleIdList></Reference><Reference><Citation>Rodr&#xed;guez-Cruz M, Cruz-Guzm&#xe1;n ODR, Almeida-Becerril T, et al. Potential therapeutic impact of omega-3 long chain-polyunsaturated fatty acids on inflammation markers in Duchenne muscular dystrophy: A double-blind, controlled randomized trial. Clin Nutr. 2018;37(6):1840&#x2013;1851. doi: 10.1016/j.clnu.2017.09.011.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.clnu.2017.09.011</ArticleId><ArticleId IdType="pubmed">28987470</ArticleId></ArticleIdList></Reference><Reference><Citation>Villaldama&#x2010;Soriano MA, Rodr&#xed;guez&#x2010;Cruz M, Hern&#xe1;ndez&#x2010;De La Cruz SY, et al. Pro&#x2010;inflammatory monocytes are increased in Duchenne muscular dystrophy and suppressed with omega&#x2010;3 fatty acids: A double&#x2010;blind, randomized, placebo&#x2010;controlled pilot study. Eur J Neurol. 2022;29(3):855&#x2013;864. doi: 10.1111/ene.15184.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/ene.15184</ArticleId><ArticleId IdType="pubmed">34779542</ArticleId></ArticleIdList></Reference><Reference><Citation>Hern&#xe1;ndez-de La Cruz SY, Ordaz-Robles T, Villaldama-Soriano MA, et al. The muscle regeneration marker FOXP3 is associated with muscle injury in Duchenne muscular dystrophy. Brain Dev. 2024;46(5):199&#x2013;206. doi: 10.1016/j.braindev.2024.02.001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.braindev.2024.02.001</ArticleId><ArticleId IdType="pubmed">38388302</ArticleId></ArticleIdList></Reference><Reference><Citation>Sitzia C, Meregalli M, Belicchi M, et al. Preliminary evidences of safety and efficacy of flavonoids- and Omega 3-based compound for muscular dystrophies treatment: a randomized double-blind placebo controlled pilot clinical trial. Front Neurol. 2019;10:755. doi: 10.3389/fneur.2019.00755.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fneur.2019.00755</ArticleId><ArticleId IdType="pmc">PMC6664031</ArticleId><ArticleId IdType="pubmed">31396142</ArticleId></ArticleIdList></Reference><Reference><Citation>Rodr&#xed;guez-Cruz M, Atilano-Miguel S, Barbosa-Cort&#xe9;s L, et al. Evidence of muscle loss delay and improvement of hyperinsulinemia and insulin resistance in Duchenne muscular dystrophy supplemented with omega-3 fatty acids: A randomized study. Clin Nutr. 2019;38(5):2087&#x2013;2097. doi: 10.1016/j.clnu.2018.10.017.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.clnu.2018.10.017</ArticleId><ArticleId IdType="pubmed">30420291</ArticleId></ArticleIdList></Reference><Reference><Citation>Pan L, Xie W, Fu X, et al. Inflammation and sarcopenia: A focus on circulating inflammatory cytokines. Exp Gerontol. 2021;154:111544. doi: 10.1016/j.exger.2021.111544.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.exger.2021.111544</ArticleId><ArticleId IdType="pubmed">34478826</ArticleId></ArticleIdList></Reference><Reference><Citation>Cruz-Guzm&#xe1;n ODR, Rodr&#xed;guez-Cruz M, Escobar-Cedillo RE. Systemic inflammation in Duchenne muscular dystrophy: association with muscle function and nutritional status. Biomed Res Int. 2015;2015:1&#x2013;7. doi: 10.1155/2015/891972.</Citation><ArticleIdList><ArticleId IdType="doi">10.1155/2015/891972</ArticleId><ArticleId IdType="pmc">PMC4561314</ArticleId><ArticleId IdType="pubmed">26380303</ArticleId></ArticleIdList></Reference><Reference><Citation>Calder PC. Functional Roles of Fatty Acids and Their Effects on Human Health. J Parenter Enter Nutr. 2015;39(1S) doi: 10.1177/0148607115595980.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/0148607115595980</ArticleId><ArticleId IdType="pubmed">26177664</ArticleId></ArticleIdList></Reference><Reference><Citation>Kavyani Z, Musazadeh V, Fathi S, et al. Efficacy of the omega-3 fatty acids supplementation on inflammatory biomarkers: An umbrella meta-analysis. Int Immunopharmacol. 2022;111:109104. doi: 10.1016/j.intimp.2022.109104.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.intimp.2022.109104</ArticleId><ArticleId IdType="pubmed">35914448</ArticleId></ArticleIdList></Reference><Reference><Citation>De Senzi-Moraes PR, Ferretti R, Moraes LHR, et al. N-Acetylcysteine treatment reduces TNF-&#x3b1; levels and myonecrosis in diaphragm muscle of mdx mice. Clin Nutr. 2013;32(3):472&#x2013;475. doi: 10.1016/j.clnu.2012.06.001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.clnu.2012.06.001</ArticleId><ArticleId IdType="pubmed">22727548</ArticleId></ArticleIdList></Reference><Reference><Citation>Kumar L, Bisen M, Khan A, et al. Role of matrix metalloproteinases in musculoskeletal diseases. Biomedicines. 2022;10(10):2477. doi: 10.3390/biomedicines10102477.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/biomedicines10102477</ArticleId><ArticleId IdType="pmc">PMC9598837</ArticleId><ArticleId IdType="pubmed">36289739</ArticleId></ArticleIdList></Reference><Reference><Citation>Pelosi L, Berardinelli MG, De Pasquale L, et al. Functional and morphological improvement of dystrophic muscle by interleukin 6 receptor blockade. EBioMedicine. 2015;2(4):285&#x2013;293. doi: 10.1016/j.ebiom.2015.02.014.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ebiom.2015.02.014</ArticleId><ArticleId IdType="pmc">PMC4485902</ArticleId><ArticleId IdType="pubmed">26137572</ArticleId></ArticleIdList></Reference><Reference><Citation>Nagata Y, Kiyono T, Okamura K, et al. Interleukin-1beta (IL-1&#x3b2;)-induced Notch ligand Jagged1 suppresses mitogenic action of IL-1&#x3b2; on human dystrophic myogenic cells. PLoS ONE. 2017;12(12):e0188821. doi: 10.1371/journal.pone.0188821.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0188821</ArticleId><ArticleId IdType="pmc">PMC5711031</ArticleId><ArticleId IdType="pubmed">29194448</ArticleId></ArticleIdList></Reference><Reference><Citation>Yao S, Chen Z, Yu Y, et al. Current pharmacological strategies for Duchenne muscular dystrophy. Front Cell Dev Biol. 2021;9:689533. doi: 10.3389/fcell.2021.689533.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fcell.2021.689533</ArticleId><ArticleId IdType="pmc">PMC8417245</ArticleId><ArticleId IdType="pubmed">34490244</ArticleId></ArticleIdList></Reference><Reference><Citation>Han X, Han J, Wang N, et al. Identification of auxiliary biomarkers and description of the immune microenvironmental characteristics in Duchenne Muscular Dystrophy by bioinformatical analysis and experiment. Front Neurosci. 2022;16:891670. doi: 10.3389/fnins.2022.891670.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fnins.2022.891670</ArticleId><ArticleId IdType="pmc">PMC9204148</ArticleId><ArticleId IdType="pubmed">35720684</ArticleId></ArticleIdList></Reference><Reference><Citation>Ono E, Lenief V, Lefevre M, et al. Topical corticosteroids inhibit allergic skin inflammation but are ineffective in impeding the formation and expansion of resident memory T cells. Allergy. 2024;79(1):52&#x2013;64. doi: 10.1111/all.15819.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/all.15819</ArticleId><ArticleId IdType="pubmed">37539746</ArticleId></ArticleIdList></Reference><Reference><Citation>Savino W, Pinto-Mariz F, Mouly V. Flow cytometry-defined CD49d expression in circulating T-lymphocytes is a biomarker for disease progression in Duchenne muscular dystrophy. Methods Mol Biol. 2018;1687:219&#x2013;227. doi: 10.1007/978-1-4939-7374-3_16.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/978-1-4939-7374-3_16</ArticleId><ArticleId IdType="pubmed">29067667</ArticleId></ArticleIdList></Reference><Reference><Citation>Shih JA, Folch A, Wong BL. Duchenne muscular dystrophy: the heart of the matter. Curr Heart Fail Rep. 2020;17(3):57&#x2013;66. doi: 10.1007/s11897-020-00456-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11897-020-00456-0</ArticleId><ArticleId IdType="pubmed">32270339</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">40267405</PMID><DateCompleted><Year>2025</Year><Month>04</Month><Day>24</Day></DateCompleted><DateRevised><Year>2025</Year><Month>05</Month><Day>21</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">2448-5667</ISSN><JournalIssue CitedMedium="Internet"><Volume>63</Volume><Issue>1</Issue><PubDate><Year>2025</Year><Month>Jan</Month><Day>03</Day></PubDate></JournalIssue><Title>Revista medica del Instituto Mexicano del Seguro Social</Title><ISOAbbreviation>Rev Med Inst Mex Seguro Soc</ISOAbbreviation></Journal><ArticleTitle>[Autosomal recessive limb-girdle muscular dystrophy-10. Case report].</ArticleTitle><Pagination><StartPage>e6447</StartPage><MedlinePgn>e6447</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">e6447</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.5281/zenodo.14201220</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="UNASSIGNED">The autosomal recessive limb-girdle muscular dystrophy-10 (LGMDR10) is a muscular dystrophy caused by pathogenetic variants in the TTN gene encoding the titin protein, which is responsible for muscle flexibility and tension. Its prevalence is unknown. The main clinical manifestations are proximal muscle weakness predominantly in the shoulder girdle and pelvic girdle, mild weakness of distal muscles and muscle atrophy. The objective is to present a case report of autosomal recessive limb-girdle muscular dystrophy-10 in a Mexican patient.</AbstractText><AbstractText Label="CLINICAL CASE" NlmCategory="UNASSIGNED">39-year-old male with hypotrophy of the left leg, muscle weakness of the 4 limbs predominantly proximal and asymmetrical, myalgia and nocturnal cramps. Total creatine phosphokinase level was of 819.7 IU/L, nerve conduction velocity and electromyography with left femoral neuropathy of the axonotmesis type and mixed axonal neuropathy with myopathic pattern of upper limbs. The molecular study for muscular dystrophies reported 2 pathogenic variants in compound heterozygous state in the TTN gene: c.107578C&gt;T (p. Gln37860*) and c.104269C&gt;T (p. Gln34767*), respectively.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="UNASSIGNED">In line with the information available, there are no reported cases of LGMDR10 in Mexico. This is a progressive disease with total loss of ambulation between the fourth and the sixth decade of life, which is why its clinical suspicion is important for a timely diagnosis, an adequate counseling, and preventive measures of complications for a better quality of life.</AbstractText><CopyrightInformation>Licencia CC 4.0 (BY-NC-ND) &#xa9; 2025 Revista M&#xe9;dica del Instituto Mexicano del Seguro Social.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>P&#xe9;rez-Arzola</LastName><ForeName>Alan Alberto</ForeName><Initials>AA</Initials><Identifier Source="ORCID">0000-0002-5984-3227</Identifier><AffiliationInfo><Affiliation>Instituto Mexicano del Seguro Social, Hospital General de Zona No. 20 "La Margarita". Servicio de Gen&#xe9;tica M&#xe9;dica. Puebla, Puebla, M&#xe9;xico.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ju&#xe1;rez-Melchor</LastName><ForeName>Daniela</ForeName><Initials>D</Initials><Identifier Source="ORCID">0000-0001-9060-7241</Identifier><AffiliationInfo><Affiliation>Instituto Mexicano del Seguro Social, Hospital General de Zona No. 20 "La Margarita". Servicio de Gen&#xe9;tica M&#xe9;dica. Puebla, Puebla, M&#xe9;xico.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Crisanto-L&#xf3;pez</LastName><ForeName>Israel Enrique</ForeName><Initials>IE</Initials><Identifier Source="ORCID">0000-0002-9448-9497</Identifier><AffiliationInfo><Affiliation>Instituto Mexicano del Seguro Social, Hospital General de Zona No. 20 "La Margarita". Servicio de Gen&#xe9;tica M&#xe9;dica. Puebla, Puebla, M&#xe9;xico.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Vera-Loaiza</LastName><ForeName>Aurea</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0002-7834-3404</Identifier><AffiliationInfo><Affiliation>Instituto Mexicano del Seguro Social, Hospital General de Zona No. 20 "La Margarita". Servicio de Gen&#xe9;tica M&#xe9;dica. Puebla, Puebla, M&#xe9;xico.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hern&#xe1;ndez-Casta&#xf1;eda</LastName><ForeName>Yazmin</ForeName><Initials>Y</Initials><Identifier Source="ORCID">0000-0003-1535-4760</Identifier><AffiliationInfo><Affiliation>Instituto Mexicano del Seguro Social, Hospital General de Zona No. 20 "La Margarita". Servicio de Gen&#xe9;tica M&#xe9;dica. Puebla, Puebla, M&#xe9;xico.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Guzm&#xe1;n-Santiago</LastName><ForeName>Tania Alejandra</ForeName><Initials>TA</Initials><Identifier Source="ORCID">0000-0001-7332-1735</Identifier><AffiliationInfo><Affiliation>Instituto Mexicano del Seguro Social, Hospital General de Zona No. 20 "La Margarita". Servicio de Gen&#xe9;tica M&#xe9;dica. Puebla, Puebla, M&#xe9;xico.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jim&#xe9;nez-P&#xe9;rez</LastName><ForeName>Berenice</ForeName><Initials>B</Initials><Identifier Source="ORCID">0000-0002-1872-0685</Identifier><AffiliationInfo><Affiliation>Instituto Mexicano del Seguro Social, Hospital General de Zona No. 20 "La Margarita". Servicio de Gen&#xe9;tica M&#xe9;dica. Puebla, Puebla, M&#xe9;xico.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rodr&#xed;guez-Hurtado</LastName><ForeName>Pablo Omar</ForeName><Initials>PO</Initials><Identifier Source="ORCID">0000-0002-5559-5393</Identifier><AffiliationInfo><Affiliation>Instituto Mexicano del Seguro Social, Hospital General de Zona No. 20 "La Margarita". Servicio de Gen&#xe9;tica M&#xe9;dica. Puebla, Puebla, M&#xe9;xico.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Salazar-Bonilla</LastName><ForeName>Wilbert</ForeName><Initials>W</Initials><Identifier Source="ORCID">0000-0003-0081-9924</Identifier><AffiliationInfo><Affiliation>Instituto Mexicano del Seguro Social, Unidad de Medicina Familiar No. 55, Servicio de Medicina Familiar. Puebla, Puebla, M&#xe9;xico.</Affiliation></AffiliationInfo></Author></AuthorList><Language>spa</Language><PublicationTypeList><PublicationType UI="D002363">Case Reports</PublicationType><PublicationType UI="D004740">English Abstract</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><VernacularTitle>Distrofia muscular de cinturas y extremidades autos&#xf3;mica recesiva 10. Reporte de caso.</VernacularTitle><ArticleDate DateType="Electronic"><Year>2025</Year><Month>01</Month><Day>03</Day></ArticleDate></Article><MedlineJournalInfo><Country>Mexico</Country><MedlineTA>Rev Med Inst Mex Seguro Soc</MedlineTA><NlmUniqueID>101243727</NlmUniqueID><ISSNLinking>0443-5117</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D064211">Connectin</NameOfSubstance></Chemical></ChemicalList><SupplMeshList><SupplMeshName Type="Disease" UI="C538640">Limb-girdle muscular dystrophy autosomal recessive</SupplMeshName></SupplMeshList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D049288" MajorTopicYN="Y">Muscular Dystrophies, Limb-Girdle</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D064211" MajorTopicYN="Y">Connectin</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading></MeshHeadingList><OtherAbstract Type="Publisher" Language="spa"><AbstractText Label="INTRODUCCI&#xd3;N" NlmCategory="UNASSIGNED">la distrofia muscular de cinturas y extremidades autos&#xf3;mica recesiva 10 (LGMDR10) es una distrofia muscular causada por variantes patog&#xe9;nicas en el gen TTN que codifica la prote&#xed;na titina, la cual es responsable de la flexibilidad y la tensi&#xf3;n muscular. Su prevalencia es desconocida. Las principales manifestaciones cl&#xed;nicas son debilidad muscular proximal de predominio en la cintura escapular y p&#xe9;lvica, leve debilidad de m&#xfa;sculos distales y atrofia muscular. El objetivo es presentar un reporte de caso de distrofia muscular de cinturas y extremidades autos&#xf3;mica recesiva 10 en un paciente mexicano.</AbstractText><AbstractText Label="CASO CL&#xcd;NICO" NlmCategory="UNASSIGNED">hombre de 39 a&#xf1;os con hipotrofia de pierna izquierda, debilidad muscular de las 4 extremidades de predominio proximal y asim&#xe9;trica, mialgias y calambres nocturnos. La creatinfosfoquinasa total fue de 819.7 UI/L, la velocidad de conducci&#xf3;n nerviosa y la electromiograf&#xed;a present&#xf3; neuropat&#xed;a femoral izquierda del tipo axonotmesis y neuropat&#xed;a mixta axonal con patr&#xf3;n miop&#xe1;tico de miembros superiores. El estudio molecular para distrofias musculares report&#xf3; 2 variantes patog&#xe9;nicas en estado heterocigoto compuesto en el gen TTN: c.107578C&gt;T (p. Gln37860*) y c.104269C&gt;T (p. Gln34767*), respectivamente.</AbstractText><AbstractText Label="CONCLUSIONES" NlmCategory="UNASSIGNED">conforme a la informaci&#xf3;n disponible, no existen casos reportados de LGMDR10 en M&#xe9;xico. Esta es una enfermedad progresiva con p&#xe9;rdida total de la deambulaci&#xf3;n entre la cuarta y la sexta d&#xe9;cada de vida, por lo que es importante su sospecha cl&#xed;nica para un diagn&#xf3;stico oportuno, un asesoramiento adecuado y la prevenci&#xf3;n de complicaciones para una mejor calidad de vida.</AbstractText><CopyrightInformation>Licencia CC 4.0 (BY-NC-ND) &#xa9; 2025 Revista M&#xe9;dica del Instituto Mexicano del Seguro Social.</CopyrightInformation></OtherAbstract><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Connectin</Keyword><Keyword MajorTopicYN="N">Muscle Weakness</Keyword><Keyword MajorTopicYN="N">Muscular Diseases</Keyword><Keyword MajorTopicYN="N">Muscular Dystrophies</Keyword><Keyword MajorTopicYN="N">Muscular Dystrophies, Limb-Girdle</Keyword></KeywordList><CoiStatement>los autores han completado y enviado la forma traducida al espa&#xf1;ol de la declaraci&#xf3;n de conflictos potenciales de inter&#xe9;s del Comit&#xe9; Internacional de Editores de Revistas M&#xe9;dicas, y no fue reportado alguno relacionado con este art&#xed;culo.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>9</Month><Day>10</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>10</Month><Day>31</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>4</Month><Day>24</Day><Hour>6</Hour><Minute>26</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>4</Month><Day>23</Day><Hour>18</Hour><Minute>30</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>4</Month><Day>23</Day><Hour>16</Hour><Minute>19</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2025</Year><Month>1</Month><Day>1</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">40267405</ArticleId><ArticleId IdType="pmc">PMC12088016</ArticleId><ArticleId IdType="doi">10.5281/zenodo.14201220</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Udd B, Vihola A, Sarparanta J, et al. Titinopathies and extension of the M-line mutation phenotype beyond distal myopathy and LGMD2J. Neurology. 2005;64(4):636&#x2013;642. doi: 10.1212/01.WNL.0000151853.50144.82.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/01.WNL.0000151853.50144.82</ArticleId><ArticleId IdType="pubmed">15728284</ArticleId></ArticleIdList></Reference><Reference><Citation>Rich KA, Moscarello T, Siskind C, et al. Novel heterozygous truncating titin variants affecting the A-band are associated with cardiomyopathy and myopathy/muscular dystrophy. Mol Genet Genomic Med. 2020;8(10):e1460. doi: 10.1002/mgg3.1460.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/mgg3.1460</ArticleId><ArticleId IdType="pmc">PMC7549586</ArticleId><ArticleId IdType="pubmed">32815318</ArticleId></ArticleIdList></Reference><Reference><Citation>Bouchard C, Tremblay JP. Limb&#x2013;Girdle Muscular Dystrophies Classification and Therapies. J Clin Med. 2023;12(14):1&#x2013;15. doi: 10.3390/jcm12144769.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/jcm12144769</ArticleId><ArticleId IdType="pmc">PMC10381329</ArticleId><ArticleId IdType="pubmed">37510884</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen Q, Zheng W, Xu H, et al. Digenic Variants in the TTN and TRAPPC11 Genes Co-segregating With a Limb-Girdle Muscular Dystrophy in a Han Chinese Family. Front Neurosci. 2021;15:601757. doi: 10.3389/fnins.2021.601757.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fnins.2021.601757</ArticleId><ArticleId IdType="pmc">PMC7969792</ArticleId><ArticleId IdType="pubmed">33746696</ArticleId></ArticleIdList></Reference><Reference><Citation>Reyes L, Villamar P, Espinosa N. Distrofia muscular de cinturas 2J, revisi&#xf3;n bibliogr&#xe1;fica y reporte de un caso pedi&#xe1;trico en Ecuador. Metro Ciencia. 2020;28(3):8&#x2013;13. doi: 10.47464/MetroCiencia/vol28/3/2020/8-13.</Citation><ArticleIdList><ArticleId IdType="doi">10.47464/MetroCiencia/vol28/3/2020/8-13</ArticleId></ArticleIdList></Reference><Reference><Citation>Georganopoulou DG, Moisiadis VG, Malik FA, et al. A Journey with LGMD: From Protein Abnormalities to Patient Impact. Protein J. 2021;40(4):466&#x2013;488. doi: 10.1007/s10930-021-10006-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10930-021-10006-9</ArticleId><ArticleId IdType="pmc">PMC8190568</ArticleId><ArticleId IdType="pubmed">34110586</ArticleId></ArticleIdList></Reference><Reference><Citation>Lombardo ME, Carraro E, Sancricca C, et al. UILDM (Italian Muscular Dystrophy Association) and Italian Consensus Conference Group on motor rehabilitation in muscular dystrophy. Management of motor rehabilitation in individuals with muscular dystrophies. 1st Consensus Conference report from UILDM - Italian Muscular Dystrophy Association (Rome, January 25-26, 2019) Acta Myol. 2021;40(2):72&#x2013;87. doi: 10.36185/2532-1900-046.</Citation><ArticleIdList><ArticleId IdType="doi">10.36185/2532-1900-046</ArticleId><ArticleId IdType="pmc">PMC8290512</ArticleId><ArticleId IdType="pubmed">34355124</ArticleId></ArticleIdList></Reference><Reference><Citation>Morishima R, Schoser B. A Straightforward Approach to Analyze Skeletal Muscle MRI in Limb-Girdle Muscular Dystrophy for Differential Diagnosis: A Systematic Review. Muscles. 2023;2:374&#x2013;388. doi: 10.3390/muscles2040029.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/muscles2040029</ArticleId></ArticleIdList></Reference><Reference><Citation>De Paepe B, Velghe E, Salminen L, et al. Diagnostic muscle biopsies in the era of genetics: the added value of myopathology in a selection of limb-girdle muscular dystrophy patients. Acta Neurol Belg. 2021;121(4):1019&#x2013;1033. doi: 10.1007/s13760-020-01559-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s13760-020-01559-0</ArticleId><ArticleId IdType="pubmed">33400223</ArticleId></ArticleIdList></Reference><Reference><Citation>Li C, Haller G, Weihl CC. Current and Future Approaches to Classify VUSs in LGMD-Related Genes. Genes (Basel) 2022;13(2):382. doi: 10.3390/genes13020382.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/genes13020382</ArticleId><ArticleId IdType="pmc">PMC8871643</ArticleId><ArticleId IdType="pubmed">35205425</ArticleId></ArticleIdList></Reference><Reference><Citation>Straub V, Murphy A, Udd B. 229th ENMC international workshop: Limb girdle muscular dystrophies &#x2013; Nomenclature and reformed classification Naarden, the Netherlands, 2018. Neuromuscul Disord. 2018;28(8):702&#x2013;710. doi: 10.1016/j.nmd.2018.05.007.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.nmd.2018.05.007</ArticleId><ArticleId IdType="pubmed">30055862</ArticleId></ArticleIdList></Reference><Reference><Citation>Savarese M, Vihola A, Oates EC, et al. Genotype-phenotype correlations in recessive titinopathies. Genet Med. 2020;22(12):2029&#x2013;2040. doi: 10.1038/s41436-020-0914-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41436-020-0914-2</ArticleId><ArticleId IdType="pubmed">32778822</ArticleId></ArticleIdList></Reference><Reference><Citation>Savarese M, Sarparanta J, Vihola A, et al. Increasing Role of Titin Mutations in Neuromuscular Disorders. J Neuromuscul Dis. 2016;3(3):293&#x2013;308. doi: 10.3233/JND-160158.</Citation><ArticleIdList><ArticleId IdType="doi">10.3233/JND-160158</ArticleId><ArticleId IdType="pmc">PMC5123623</ArticleId><ArticleId IdType="pubmed">27854229</ArticleId></ArticleIdList></Reference><Reference><Citation>Misaka T, Yoshihisa A, Takeishi Y. Titin in muscular dystrophy and cardiomyopathy: Urinary titin as a novel marker. Clin Chim Acta. 2019;495:123&#x2013;128. doi: 10.1016/j.cca.2019.04.005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cca.2019.04.005</ArticleId><ArticleId IdType="pubmed">30959043</ArticleId></ArticleIdList></Reference><Reference><Citation>Nigro V, Savarese M. Genetic basis of limb-girdle muscular dystrophies: The 2014 update. Acta Myol. 2014;33(1):1&#x2013;12.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4021627</ArticleId><ArticleId IdType="pubmed">24843229</ArticleId></ArticleIdList></Reference><Reference><Citation>Leo&#x144;ska-Duniec A, Borczyk M, Piechota M, et al. TTN Variants Are Associated with Physical Performance and Provide Potential Markers for Sport-Related Phenotypes. Int J Environ Res Public Health. 2022;19(16):10173. doi: 10.3390/ijerph191610173.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijerph191610173</ArticleId><ArticleId IdType="pmc">PMC9408402</ArticleId><ArticleId IdType="pubmed">36011809</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen Q, Zheng W, Xu H, et al. Digenic Variants in the TTN and TRAPPC11 Genes Co-segregating With a Limb-Girdle Muscular Dystrophy in a Han Chinese Family. Front Neurosci. 2021;15:601757. doi: 10.3389/fnins.2021.601757.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fnins.2021.601757</ArticleId><ArticleId IdType="pmc">PMC7969792</ArticleId><ArticleId IdType="pubmed">33746696</ArticleId></ArticleIdList></Reference><Reference><Citation>Loescher CM, Hobbach AJ, Linke WA. Titin (TTN): from molecule to modifications, mechanics, and medical significance. Cardiovasc Res. 2022;118(14):2903&#x2013;2918. doi: 10.1093/cvr/cvab328.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/cvr/cvab328</ArticleId><ArticleId IdType="pmc">PMC9648829</ArticleId><ArticleId IdType="pubmed">34662387</ArticleId></ArticleIdList></Reference><Reference><Citation>Jolfayi AG, Kohansal E, Ghasemi S, et al. Exploring TTN variants as genetic insights into cardiomyopathy pathogenesis and potential emerging clues to molecular mechanisms in cardiomyopathies. Sci Rep. 2024;14(1):5313. doi: 10.1038/s41598-024-56154-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-024-56154-7</ArticleId><ArticleId IdType="pmc">PMC10912352</ArticleId><ArticleId IdType="pubmed">38438525</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang G, Lv X, Xu L, et al. Novel compound heterozygous mutations in the TTN gene: elongation and truncation variants causing limb-girdle muscular dystrophy type 2J in a Han Chinese family. Neurol Sci. 2022;43(5):3427&#x2013;3433. doi: 10.1007/s10072-022-05979-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10072-022-05979-z</ArticleId><ArticleId IdType="pubmed">35239051</ArticleId></ArticleIdList></Reference><Reference><Citation>Rees M, Nikoopour R, Fukuzawa A, et al. Making sense of missense variants in TTN-related congenital myopathies. Acta Neuropathol. 2021;141(3):431&#x2013;453. doi: 10.1007/s00401-020-02257-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-020-02257-0</ArticleId><ArticleId IdType="pmc">PMC7882473</ArticleId><ArticleId IdType="pubmed">33449170</ArticleId></ArticleIdList></Reference><Reference><Citation>P&#xe9;nisson-Besnier I, Hackman P, Suominen T, et al. Myopathies caused by homozygous titin mutations: Limb-girdle muscular dystrophy 2J and variations of phenotype. J Neurol Neurosurg Psychiatry. 2010;81(11):1200&#x2013;1202.</Citation><ArticleIdList><ArticleId IdType="pubmed">20571043</ArticleId></ArticleIdList></Reference><Reference><Citation>Khan A, Wang R, Han S, et al. Homozygous missense variant in the TTN gene causing autosomal recessive limb-girdle muscular dystrophy type 10. BMC Med Genet. 2019;20(1):166. doi: 10.1186/s12881-019-0895-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12881-019-0895-7</ArticleId><ArticleId IdType="pmc">PMC6819411</ArticleId><ArticleId IdType="pubmed">31664938</ArticleId></ArticleIdList></Reference><Reference><Citation>Pozsgai E, Griffin D, Potter R, et al. Unmet needs and evolving treatment for limb girdle muscular dystrophies. Neurodegener Dis Manag. 2021;11(5):411&#x2013;429. doi: 10.2217/nmt-2020-0066.</Citation><ArticleIdList><ArticleId IdType="doi">10.2217/nmt-2020-0066</ArticleId><ArticleId IdType="pubmed">34472379</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">40198163</PMID><DateCompleted><Year>2025</Year><Month>04</Month><Day>08</Day></DateCompleted><DateRevised><Year>2025</Year><Month>04</Month><Day>08</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1669-9106</ISSN><JournalIssue CitedMedium="Internet"><Volume>85</Volume><Issue>2</Issue><PubDate><Year>2025</Year></PubDate></JournalIssue><Title>Medicina</Title><ISOAbbreviation>Medicina (B Aires)</ISOAbbreviation></Journal><ArticleTitle>Duchenne muscular distrophy in Taf&#xed; del Valle, Tucum&#xe1;n, Argentina.</ArticleTitle><Pagination><StartPage>281</StartPage><EndPage>286</EndPage><MedlinePgn>281-286</MedlinePgn></Pagination><Abstract><AbstractText Label="INTRODUCTION" NlmCategory="BACKGROUND">Duchenne muscular dystrophy (DMD) is an inherited, X-linked neuromuscular disorder with a global cumulative prevalence of 7.1 cases every 100 000 males. A relationship between consanguinity and DMD has been reported. We aimed to describe the prevalence and the sociodemographic, clinical and genetic characteristics of patients with DMD in an isolated population in Taf&#xed; del Valle (Tucum&#xe1;n, Argentina).</AbstractText><AbstractText Label="MATERIALS AND METHODS" NlmCategory="METHODS">Cross-sectional, descriptive, epidemiological study. Demographic, clinical and genetic data were retrieved from medical records. Pedigree charts were made after an interview with the family group.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Seven male patients with DMD of DiaguitaCalchaqu&#xed; ethnicity were identified (median age: 14 years old), with a prevalence of 0.12%. Five different mutations were reported. No consanguinity was identified in pedigree charts.</AbstractText><AbstractText Label="DISCUSSION" NlmCategory="CONCLUSIONS">An unusual high prevalence of DMD was identified in Taf&#xed; del Valle. In addition, there are 5 different mutations in seven patients suggesting a high number of mutations "de novo".</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Sarandr&#xed;a</LastName><ForeName>Mar&#xed;a Eugenia</ForeName><Initials>ME</Initials><AffiliationInfo><Affiliation>Residencia de Neurolog&#xed;a, Fundaci&#xf3;n para la Lucha contra las Enfermedades Neurol&#xf3;gicas de la Infancia (FLENI), Buenos Aires, Argentina. E-mail: mesarandria@gmail.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rey</LastName><ForeName>Roberto</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Instituto Argentino de Investigaci&#xf3;n Neurol&#xf3;gica, Buenos Aires, Argentina.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>De Rosa</LastName><ForeName>Rodrigo</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Hospital El&#xed;as Medici, Taf&#xed; del Valle, Tucum&#xe1;n, Argentina.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Corbal&#xe1;n</LastName><ForeName>Vanesa</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>Centro de Rehabilitaci&#xf3;n Los Menhires, Hospital El&#xed;as Medici, Taf&#xed; del Valle, Tucum&#xe1;n, Argentina.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mesa</LastName><ForeName>Lilia</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Secci&#xf3;n Neuromuscular Pedi&#xe1;trica, Fundaci&#xf3;n Favaloro, Buenos Aires, Argentina.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><VernacularTitle>Distrofia muscular de Duchenne en Taf&#xed; del Valle, Tucum&#xe1;n, Argentina.</VernacularTitle></Article><MedlineJournalInfo><Country>Argentina</Country><MedlineTA>Medicina (B Aires)</MedlineTA><NlmUniqueID>0204271</NlmUniqueID><ISSNLinking>0025-7680</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001118" MajorTopicYN="N" Type="Geographic">Argentina</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D020388" MajorTopicYN="Y">Muscular Dystrophy, Duchenne</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003430" MajorTopicYN="N">Cross-Sectional Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015995" MajorTopicYN="N">Prevalence</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009154" MajorTopicYN="N">Mutation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002648" MajorTopicYN="N">Child</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010375" MajorTopicYN="N">Pedigree</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D055815" MajorTopicYN="N">Young Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003241" MajorTopicYN="N">Consanguinity</DescriptorName></MeshHeading></MeshHeadingList><OtherAbstract Type="Publisher" Language="spa"><AbstractText>Introducci&#xf3;n: La distrofia muscular de Duchenne (DMD) es un trastorno neuromuscular hereditario ligado al cromosoma X con una prevalencia global acumulada de 7.1 casos cada 100.000 varones. Se observa una relaci&#xf3;n entre consanguinidad y DMD. Nuestro objetivo fue describir la prevalencia y las caracter&#xed;sticas sociodemogr&#xe1;ficas, cl&#xed;nicas y gen&#xe9;ticas de los pacientes con DMD en una poblaci&#xf3;n aislada de Taf&#xed; del Valle (Tucum&#xe1;n, Argentina). Materiales y m&#xe9;todos: Estudio epidemiol&#xf3;gico, descriptivo y transversal. Se recuperaron datos demogr&#xe1;ficos, cl&#xed;nicos y gen&#xe9;ticos de las historias cl&#xed;nicas. Se elaboraron genogramas a partir de entrevistas con el grupo familiar. Resultados: Siete pacientes varones con DMD de etnia Diaguita-Calchaqu&#xed; fueron identificados (mediana de edad: 14 a&#xf1;os), con una prevalencia de 0.12 %. Se reportaron cinco mutaciones diferentes. No se identific&#xf3; consanguinidad a trav&#xe9;s de los genogramas. Discusi&#xf3;n: Se identific&#xf3; una prevalencia inusual y elevada de DMD en Taf&#xed; del Valle. No encontramos consanguinidad que explique este hallazgo y se describen en los 7 pacientes, 5 mutaciones diferentes, lo cual podr&#xed;a deberse a un alto n&#xfa;mero de mutaciones de novo.</AbstractText></OtherAbstract><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Argentina</Keyword><Keyword MajorTopicYN="N">Duchenne</Keyword><Keyword MajorTopicYN="N">muscular dystrophy</Keyword><Keyword MajorTopicYN="N">prevalence</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>4</Month><Day>8</Day><Hour>13</Hour><Minute>56</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>4</Month><Day>8</Day><Hour>13</Hour><Minute>55</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>4</Month><Day>8</Day><Hour>12</Hour><Minute>23</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">40198163</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">40120751</PMID><DateCompleted><Year>2025</Year><Month>05</Month><Day>29</Day></DateCompleted><DateRevised><Year>2025</Year><Month>05</Month><Day>29</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">2173-5794</ISSN><JournalIssue CitedMedium="Internet"><Volume>100</Volume><Issue>5</Issue><PubDate><Year>2025</Year><Month>May</Month></PubDate></JournalIssue><Title>Archivos de la Sociedad Espanola de Oftalmologia</Title><ISOAbbreviation>Arch Soc Esp Oftalmol (Engl Ed)</ISOAbbreviation></Journal><ArticleTitle>Retinopathy associated with facioscapulohumeral muscular dystrophy. A case report treated with intravitreal dexamethasone implant and laser photocoagulation.</ArticleTitle><Pagination><StartPage>283</StartPage><EndPage>288</EndPage><MedlinePgn>283-288</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.oftale.2025.03.014</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S2173-5794(25)00040-4</ELocationID><Abstract><AbstractText>Facioscapulohumeral muscular dystrophy (FSHD) is a slowly progressive muscular dystrophy that affects especially the muscles of the face, shoulder girdle and upper arms. It may present extramuscular manifestations such as hearing loss and retinopathy. Up to 75% of patients may show alterations in the retinal vasculature such as vascular tortuosity, microaneurysms, telangiectasias, retinal ischemia and exudation, and in less than 1% of cases it may present as Coats-like syndrome. We present a 40-year-old male with FSHD who, in an ophthalmologic examination, showed exudative retinopathy in his left eye (LE) with peripheral retinal ischemia treated with laser therapy, and macular edema (ME) treated with intravitreal dexamethasone injection (IDI). We would like to emphasize the importance of performing an ophthalmological examination on all patients with FSHD to rule out associated retinal pathology, and thus prevent loss of visual acuity (VA) with early treatment.</AbstractText><CopyrightInformation>Copyright &#xa9; 2025 Sociedad Espa&#xf1;ola de Oftalmolog&#xed;a. Published by Elsevier Espa&#xf1;a, S.L.U. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Gonz&#xe1;lez Escobar</LastName><ForeName>A B</ForeName><Initials>AB</Initials><AffiliationInfo><Affiliation>Departamento de Oftalmolog&#xed;a, Hospital Virgen de la Victoria, M&#xe1;laga, Spain. Electronic address: abgonzalezescobar@gmail.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Molina Guilabert</LastName><ForeName>I E</ForeName><Initials>IE</Initials><AffiliationInfo><Affiliation>Departamento de Oftalmolog&#xed;a, Hospital Virgen de la Victoria, M&#xe1;laga, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Garc&#xed;a Herrera</LastName><ForeName>R M</ForeName><Initials>RM</Initials><AffiliationInfo><Affiliation>Departamento de Oftalmolog&#xed;a, Hospital Virgen de la Victoria, M&#xe1;laga, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Baquero Aranda</LastName><ForeName>I M</ForeName><Initials>IM</Initials><AffiliationInfo><Affiliation>Departamento de Oftalmolog&#xed;a, Hospital Virgen de la Victoria, M&#xe1;laga, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Luque Aranda</LastName><ForeName>R</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Departamento de Oftalmolog&#xed;a, Hospital Virgen de la Victoria, M&#xe1;laga, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Galv&#xe1;n Cano</LastName><ForeName>J M</ForeName><Initials>JM</Initials><AffiliationInfo><Affiliation>Departamento de Oftalmolog&#xed;a, Hospital Virgen de la Victoria, M&#xe1;laga, Spain.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D002363">Case Reports</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2025</Year><Month>03</Month><Day>20</Day></ArticleDate></Article><MedlineJournalInfo><Country>Spain</Country><MedlineTA>Arch Soc Esp Oftalmol (Engl Ed)</MedlineTA><NlmUniqueID>101715860</NlmUniqueID><ISSNLinking>2173-5794</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>7S5I7G3JQL</RegistryNumber><NameOfSubstance UI="D003907">Dexamethasone</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D004343">Drug Implants</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D005938">Glucocorticoids</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020391" MajorTopicYN="Y">Muscular Dystrophy, Facioscapulohumeral</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003907" MajorTopicYN="Y">Dexamethasone</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017075" MajorTopicYN="Y">Laser Coagulation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D058449" MajorTopicYN="N">Intravitreal Injections</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012164" MajorTopicYN="Y">Retinal Diseases</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000601" MajorTopicYN="N">surgery</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008269" MajorTopicYN="N">Macular Edema</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000601" MajorTopicYN="N">surgery</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004343" MajorTopicYN="N">Drug Implants</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005938" MajorTopicYN="Y">Glucocorticoids</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003131" MajorTopicYN="N">Combined Modality Therapy</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Dexamethasone intravitreal implant</Keyword><Keyword MajorTopicYN="N">Distrofia muscular facioescapulohumeral</Keyword><Keyword MajorTopicYN="N">Edema macular</Keyword><Keyword MajorTopicYN="N">Facioscapulohumeral muscular dystrophy</Keyword><Keyword MajorTopicYN="N">Implante intrav&#xed;treo de dexametasona</Keyword><Keyword MajorTopicYN="N">Isquemia perif&#xe9;rica</Keyword><Keyword MajorTopicYN="N">Macular edema</Keyword><Keyword MajorTopicYN="N">Optical coherence tomography</Keyword><Keyword MajorTopicYN="N">Peripheral ischemia</Keyword><Keyword MajorTopicYN="N">Retinal telangiectasia</Keyword><Keyword MajorTopicYN="N">Telangiectasias retinianas</Keyword><Keyword MajorTopicYN="N">Tomograf&#xed;a de coherencia &#xf3;ptica</Keyword></KeywordList><CoiStatement>Conflicts of interests None declared.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>8</Month><Day>30</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2025</Year><Month>1</Month><Day>3</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>5</Month><Day>30</Day><Hour>1</Hour><Minute>58</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>3</Month><Day>23</Day><Hour>16</Hour><Minute>51</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>3</Month><Day>22</Day><Hour>20</Hour><Minute>36</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">40120751</ArticleId><ArticleId IdType="doi">10.1016/j.oftale.2025.03.014</ArticleId><ArticleId IdType="pii">S2173-5794(25)00040-4</ArticleId></ArticleIdList></PubmedData></PubmedArticle></PubmedArticleSet>